Skip to main content
. Author manuscript; available in PMC: 2021 Jan 15.
Published in final edited form as: Neuroscience. 2019 Nov 26;425:280–300. doi: 10.1016/j.neuroscience.2019.11.020

Figure 5. MDZ + 500 mg/kg propylparaben does not demonstrate significant anticonvulsant or neuroprotective properties in soman (A) and DFP (B) models of SE.

Figure 5.

Ai) Change in gamma power relative to baseline in soman-exposed rats that received MDZ + 500 mg/kg propylparaben (grey, n=7) or MDZ + saline (blue, n=10). Aii) Change in mean spike rate frequency relative to baseline in soman-exposed rats that received MDZ + 500 mg/kg propylparaben (grey, n=7) or MDZ + saline (blue, n=10). Aiii) Fluoro-Jade B staining in vulnerable brain regions in soman-exposed rats that received MDZ + 500 mg/kg propylparaben (grey, n=7) or MDZ + saline (blue, n=17). Bi) Change in gamma power relative to baseline in DFP-exposed rats that received MDZ + 500 mg/kg propylparaben (grey, n=17) or MDZ + PEG200 (blue, n=17). Bii) Change in mean spike rate frequency relative to baseline in DFP-exposed rats that received MDZ + 500 mg/kg propylparaben (grey, n=17) or MDZ + PEG200 (blue, n=17). Biii) Fluoro-Jade B staining in vulnerable brain regions in DFP-exposed rats that received MDZ + 500 mg/kg propylparaben (grey, n=17) or MDZ + PEG200 (blue, n=17). Data represents mean ± SEM. Statistical significance: *p<0.05.